Arca
Skip to content
Tools
Tools

Phosphodiesterase 4

Family in Homo sapiens that 24 drugs act on.

  • Drugs that act on it: 24
  • Approved: 10
  • In phases 1 to 3: 14
  • Sponsors: 17
  • Genes: 4

Who is on it, and how far along

Every drug ChEMBL records acting on PDE4A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 23
  • Protein or peptide 1

Approved10

  • Apremilast
  • Roflumilast
  • Crisaborole
  • Ensifentrine
  • Ibudilast
  • Dyphylline
  • Theophylline anhydrous
  • Amlexanox
  • Flavoxate
  • Theophylline glycinate

Phase 34

  • Difamilast
  • Cilomilast
  • Drotaverine
  • Tetomilast

Phase 210

  • Dovramilast
  • GSK-256066
  • HT-0712
  • Lotamilast
  • MK-0873
  • Oglemilast
  • Revamilast
  • Rolipram
  • Tofimilast
  • Tranimilast

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Phosphodiesterase 4 inhibitor.
    ApremilastApprovedAmgenSmall moleculeInhibitor30
    RoflumilastApprovedAstraZeneca PharmaceuticalsSmall moleculeInhibitor25
    CrisaboroleApprovedPfizerSmall moleculeInhibitor9
    EnsifentrineApprovedMerck & Co. (MSD)Small moleculeInhibitor3
    IbudilastApprovedMediciNovaSmall moleculeInhibitor2
    DyphyllineApprovedTeva Pharmaceutical IndustriesSmall moleculeInhibitor1
    Theophylline anhydrousApprovedOrganonProtein or peptideInhibitor1
    AmlexanoxApprovedULURUSmall moleculeInhibitor0
    FlavoxateApprovedJohnson & JohnsonSmall moleculeInhibitor0
    Theophylline glycinateApprovedCent PharmaceuticalsSmall moleculeInhibitor0
    DifamilastPhase 3Acrotech BiopharmaSmall moleculeInhibitor2
    CilomilastPhase 3GSKSmall moleculeInhibitor0
    DrotaverinePhase 3—Small moleculeInhibitor0
    TetomilastPhase 3Otsuka PharmaceuticalSmall moleculeInhibitor0
    DovramilastPhase 2AmgenSmall moleculeInhibitor1
    GSK-256066Phase 2GSKSmall moleculeInhibitor0
    HT-0712Phase 2Dart NeuroScience, LLCSmall moleculeInhibitor0
    LotamilastPhase 2OrganonSmall moleculeInhibitor0
    MK-0873Phase 2Merck & Co. (MSD)Small moleculeInhibitor0
    OglemilastPhase 2AbbVieSmall moleculeInhibitor0
    RevamilastPhase 2Glenmark PharmaceuticalsSmall moleculeInhibitor0
    RolipramPhase 2GSKSmall moleculeInhibitor0
    TofimilastPhase 2PfizerSmall moleculeInhibitor0
    TranimilastPhase 2Chiesi FarmaceuticiSmall moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 33 in all, from ClinicalTrials.gov.
    Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisRoflumilastPhase 3RecruitingArcutis Biotherapeutics, Inc.Nov 4, 2026
    Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release FormulationApremilastPhase 1RecruitingAmgenNov 2, 2026
    Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.CrisaborolePhase 3RecruitingCairo UniversityOct 29, 2026
    Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease PatientsRoflumilastPhase 2 / Phase 3Not yet recruitingTanta UniversityOct 28, 2026
    Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis.CrisaborolePhase 3Not yet recruitingCairo UniversityOct 23, 2026
    Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)EnsifentrinePhase 3RecruitingMerck Sharp & Dohme LLCOct 15, 2026
    Apremilast Added to Antihistamines in Chronic UrticariaApremilastPhase 2Enrolling by invitationRashid Latif Medical CollegeSep 30, 2026
    Comparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis PhenotypeRoflumilastPhase 4Not yet recruitingSidra AzizAug 31, 2026
    An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail PsoriasisRoflumilastPhase 4RecruitingModern Research Associates, PLLCJul 24, 2026
    Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis SuppurativaRoflumilastPhase 2RecruitingHarrison DermatologyJul 8, 2026
    Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic DermatitisRoflumilastPhase 3RecruitingHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Jul 6, 2026
    An Open-label, Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Cutaneous Adverse Events Due to Checkpoint InhibitorsRoflumilastPhase 2Not yet recruitingMassachusetts General HospitalJun 10, 2026
    Effect of Roflumilast as Add-On Therapy in Rheumatoid ArthritisRoflumilastPhase 2RecruitingHorus UniversityJun 8, 2026
    EFFICACY OF ROFLUMILAST IN THE TREATMENT OF FLEXURAL AND/OR GENITAL PSORIASIS: A RANDOMIZED CONTROLLED TRIAL.ApremilastPhase 2Not yet recruitingEman Raafat SaidApr 22, 2026
    A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 WeeksCrisaboroleNot applicableNot yet recruitingFoundation University IslamabadApr 9, 2026
    Theophylline, Versus Sumatriptan and Gabapentin in The Treatment of Post-Dural Puncture HeadacheTheophylline anhydrousNot applicableRecruitingTanta UniversityApr 7, 2026
    Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic EczemaCrisaborolePhase 4Not yet recruitingJinnah Postgraduate Medical CentreFeb 27, 2026
    Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic DermatitisCrisaborolePhase 4Not yet recruitingHayat Abad Medical Complex, PeshawarFeb 27, 2026
    Methotrexate Versus Apremilast for Pruritus in PsoriasisApremilastPhase 4Not yet recruitingZarmeen KhawarFeb 25, 2026
    Apremilast and Adalimumab in Psoriatic Arthritis PatientsApremilastNot applicableNot yet recruitingTanta UniversityFeb 10, 2026
    Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque PsoriasisApremilastNot applicableNot yet recruitingAssiut UniversityJan 26, 2026
    Comparative Study of Crisaborole vs. Tacrolimus in Atopic DermatitisCrisaborolePhase 4Not yet recruitingCairo UniversityJan 26, 2026
    Utilization of a Microdevice for Psoriasis and Atopic DermatitisApremilast, CrisaborolePhase 4Not yet recruitingUniversity of California, San FranciscoJan 20, 2026
    To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care HospitalApremilastEarly phase 1RecruitingSyeda Sana ZamanJan 13, 2026
    A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic DermatitisDifamilastPhase 3Not yet recruitingOtsuka Pharmaceutical Co., Ltd.Sep 22, 2025
    A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic DermatitisDifamilastPhase 3Not yet recruitingOtsuka Pharmaceutical Co., Ltd.Sep 15, 2025
    Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 ReactionDovramilastPhase 2RecruitingMedicines Development for Global HealthSep 15, 2025
    Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic DermatitisCrisaborolePhase 3Not yet recruitingShalamar Institute of Health SciencesSep 9, 2025
    A Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisEnsifentrinePhase 2RecruitingVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAAug 19, 2024
    Ibudilast for Treating Alcohol Use DisorderIbudilastPhase 2Active, not recruitingUniversity of PennsylvaniaJun 10, 2022
    Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)EnsifentrinePhase 2Active, not recruitingVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAMar 8, 2022
    Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSIbudilastPhase 2 / Phase 3Active, not recruitingMediciNovaAug 15, 2019
    DILIN - Prospective StudyDyphylline—RecruitingDuke UniversityJun 29, 2006

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2093863, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.